Evidence map›Paper›PMID 40899147›Full record

SynthesisActa neuropsychiatrica2025

Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.

Hezekiah C T Au, Pak Ho Lam, Fateen Kabir, Chen Lily Huang, Christine E Dri, Gia Han Le, Angela T H Kwan, Sabrina Wong, Kayla M Teopiz, Roger S McIntyre

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta neuropsychiatrica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hezekiah C T AuInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0009-0002-8786-1550
Pak Ho LamInstitute of Epidemiology and Health Care, University College London, London, UK.
Fateen KabirBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Chen Lily HuangBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Christine E DriBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Gia Han LeInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.
Angela T H KwanBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Sabrina WongInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.
Kayla M TeopizBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Roger S McIntyreDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0003-4733-2523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExtant literature indicated that glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may potentially reduce risk of opioid overdose in persons with opioid use disorders (OUDs). Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on OUDs.

methodsWe examined preclinical and clinical paradigms examining the effects of GLP-1 and GLP-1 RAs on OUD and OUD-associated behaviours (i.e. opioid self-administration, opioid-seeking behaviour). Relevant articles were retrieved from OVID (MedLine, Embase, AMED, PsychINFO, and JBI EBP Database), PubMed, and Web of Science from database inception to 1 May 2025. Primary studies (

resultsGLP-1 RAs (i.e. exenatide, liraglutide) reduced opioid-seeking behaviour (

conclusionGLP-1 RAs may affect opioid self-administration as well as the risk for overdose as evidenced by both preclinical and clinical data. There is a need for adequate well-controlled studies to determine whether GLP-1 RAs may provide clinically meaningful improvement and risk reduction in persons living with OUDs.

Indexed as

ExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideOpioid-Related DisordersAnalgesics, OpioidAnimalsHumansOpiate OverdoseAnalgesics, OpioidExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideExenatideglucagon-like peptide-1liraglutideopioid use disordersubstance use disorder

Identifiers

PMID40899147
PMCPMC13130282

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.